Literature DB >> 237834

Biochemical and immunological properties of ribonucleic acid-rich extracts from Francisella tularensis.

I I Andron LA, H T Eigelsbach.   

Abstract

Ribonucleic acid (RNA)-rich extracts derived from the attenuated strain of Francisella tularensis (strain LVS) protected Swiss mice against lethal challenge with F. tularensis strain 425 but not against strain SCHU S4. No killed preparation, including an RNA-rich extract from SCHU S4 itself, offered protection against strain SCHU S4 in contrast to the high level of protection offered against this strain by vaccination with live strain LVS. The protective activity observed against strain 425 was sensitive to ribonuclease but not to Pronase. Protective activity is not a general property of bacterial RNA, since RNA-rich extracts from Staphylococcus aureus offered no protection against tularemia, although disc gel electrophoresis showed similar kinds and amounts of RNA in preparations form F. tularensis and S. aureus. Furthermore, inability to localize activity to a specific region in sucrose gradients suggests a structural rather than an informational role for the RNA in such extracts. RNA-rich extracts from F. tularensis but not from S. aureus were efficient inducers of F. tularensis opsonins in mouse serum, suggesting one mechanism by which such extracts confer protection.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 237834      PMCID: PMC415257          DOI: 10.1128/iai.12.1.137-142.1975

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  28 in total

1.  Induction of antibody synthesis by purified immunogenic RNA in vitro.

Authors:  L J Duke; C Miller; S Harshman
Journal:  Nat New Biol       Date:  1972-02-09

2.  Formation of antibody in rabbit spleen cell cultures stimulated with immunogenic RNA.

Authors:  H K Meiss; M Fishman
Journal:  J Immunol       Date:  1972-05       Impact factor: 5.422

3.  The effect of metabolic inhibitors and hydroxylamine on the immune response in mice to mycobacterial ribonucleic acid vaccines.

Authors:  A S Youmans; G P Youmans
Journal:  J Immunol       Date:  1974-01       Impact factor: 5.422

4.  Immune cytolysis of human tumor cells mediated by xenogeneic "immune" RNA.

Authors:  L L Veltman; D H Kern; Y H Pilch
Journal:  Cell Immunol       Date:  1974-09       Impact factor: 4.868

5.  Protection against Toxoplasma gondii in mice immunized with Toxoplasma cell fractions, RNA and synthetic polyribonucleotides.

Authors:  F G Araujo; J S Remington
Journal:  Immunology       Date:  1974-10       Impact factor: 7.397

6.  Phagocytosis of Francisella tularensis by Rhesus monkey peripheral leukocytes.

Authors:  R A Proctor; J D White; E Ayala; P G Canonico
Journal:  Infect Immun       Date:  1975-01       Impact factor: 3.441

7.  Relationship between tuberculin hypersensitivity and cellular immunity to infection in mice vaccinated with viable attenuated Mycobacterial cells or with Mycobacterial ribonucleic acid preparations.

Authors:  R G Neiburger; G P Youmans; A S Youmans
Journal:  Infect Immun       Date:  1973-07       Impact factor: 3.441

8.  Detection of delayed hypersensitivity in mice injected with ribonucleic acid-protein fractions of Salmonella typhimurium.

Authors:  R A Smith; N J Bigley
Journal:  Infect Immun       Date:  1972-09       Impact factor: 3.441

9.  Ribonucleic acid-protein fractions of virulent Salmonella typhimurium as protective immunogens.

Authors:  R A Smith; N J Bigley
Journal:  Infect Immun       Date:  1972-09       Impact factor: 3.441

10.  Phagocytosis of live versus heat-killed bacteria by human polymorphonuclear leukocytes.

Authors:  L R DeChatelet; D Mullikin; P S Shirley; C E McCall
Journal:  Infect Immun       Date:  1974-07       Impact factor: 3.441

View more
  16 in total

1.  Role of interferon in mice in protection against influenza A virus by bacterial ribosomes together with membranal glycoproteins of Klebsiella pneumoniae as adjuvant.

Authors:  D Robert; J P Quillon; B Ivanoff; Y Beaudry; R Fontanges; G Normier; A M Pinel; L D D'hinterland
Journal:  Infect Immun       Date:  1979-11       Impact factor: 3.441

2.  Humoral immunity to Streptococcus pneumoniae induced by a pneumococcal ribosomal protein fraction.

Authors:  C L Swendsen; W Johnson
Journal:  Infect Immun       Date:  1976-08       Impact factor: 3.441

3.  Immuno-stimulation by a ribosomal vaccine associated with a bacterial cell wall adjuvant in humans.

Authors:  F B Michel; L Dussourd D'Hinterland; J Bousquet; A M Pinel; G Normier
Journal:  Infect Immun       Date:  1978-06       Impact factor: 3.441

4.  Characterization of the immunoprotective antigen of ribosomal preparations from Haemophilus influenzae.

Authors:  R P Tewari; M Lynn; A J Birnbaum; M Solotorovsky
Journal:  Infect Immun       Date:  1978-01       Impact factor: 3.441

5.  Immunoprotective activity of ribosomes from Haemophilus influenzae.

Authors:  M Lynn; R P Tewari; M Solotorovsky
Journal:  Infect Immun       Date:  1977-02       Impact factor: 3.441

6.  Direct evidence for the presence of lipopolysaccharide components in Pseudomonas ribosomal vaccine.

Authors:  M M Lieberman
Journal:  Infect Immun       Date:  1977-08       Impact factor: 3.441

7.  Ribonuclease-sensitive ribosomal vaccines.

Authors:  R Gonggrijp; A C Antonissen; J F van den Bosch; C P van Boven
Journal:  Antonie Van Leeuwenhoek       Date:  1984       Impact factor: 2.271

8.  Serotype-nonspecific protection induced by ribonucleic acid isolated from the ribosomal vaccine of Pseudomonas aeruginosa.

Authors:  R Gonggrijp; W J Mullers; C P van Boven
Journal:  Infect Immun       Date:  1981-07       Impact factor: 3.441

9.  Variability of protection in inbred mice induced by a ribosomal vaccine prepared from Salmonella typhimurium.

Authors:  M L Misfeldt; W Johnson
Journal:  Infect Immun       Date:  1976-09       Impact factor: 3.441

10.  Immunogenicity of ribosomal preparations from Neisseria gonorrhoeae.

Authors:  M D Cooper; R P Tewari; D V Bowser
Journal:  Infect Immun       Date:  1980-04       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.